ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Nervous System Diseases
Central Nervous System Diseases

Alzheimer's Disease trials near Toronto, ON, CAN:

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in p...

Enrolling
Alzheimer's Disease
Biological: VHB937
Other: Placebo

Phase 2

Novartis
Novartis

Toronto, Ontario, Canada and 7 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Toronto, Ontario, Canada and 35 other locations

the safety and efficacy of the ExAblate® Model 4000 Type 2.0 system as a tool to open the blood-brain barrier (BBB) in patients with probable Alzheimer's...

Enrolling
Alzheimer Disease
Device: Blood Brain Barrier (BBB) Disruption
InSightec
InSightec

Toronto, Ontario, Canada

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Toronto, Ontario, Canada and 37 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Active, not recruiting
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Toronto, Ontario, Canada and 109 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Phase 2

Acumen Pharmaceuticals

Toronto, Ontario, Canada and 72 other locations

Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease...

Enrolling
Alzheimer's Disease
Other: Placebo
Drug: KarXT

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Toronto, Ontario, Canada and 111 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab SC
Drug: Lecanemab IV

Phase 3

Eisai
Eisai

Toronto, Ontario, Canada and 246 other locations

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...

Active, not recruiting
Alzheimer's Disease
Drug: GSK4527226
Other: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Toronto, Ontario, Canada and 96 other locations

55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).The primary objective is to ev...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: ML-007C-MA
Drug: Placebo

Phase 2

MapLight Therapeutics

Toronto, Ontario, Canada and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems